Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Betaine Addition to Water Loading Prior to Running Exercise

18 september 2026 uppdaterad av: Emilia Zawieja, Poznan University of Life Sciences

Effects of a Betaine-Supplemented Hydration Protocol on Sweat Rate and Exercise Performance in Runners

This randomized, double-blind, placebo-controlled crossover study will investigate whether acute betaine ingestion as part of a pre-exercise hyperhydration strategy improves endurance running performance and influences hydration-related responses during prolonged exercise.

Approximately 30 recreationally trained male and premenopausal female runners will complete two experimental trials: a betaine condition and a placebo/control condition. In the betaine condition, participants will ingest anhydrous betaine at a dose of 0.07 g/kg body mass as part of a standardized pre-exercise hydration protocol providing a total fluid intake of approximately 25 mL/kg body mass.

Following the hydration protocol, participants will complete 60 minutes of treadmill running at 60% of the running velocity corresponding to VO₂max, followed by a 5-minute recovery period and a 5-km treadmill time trial.

The primary outcome will be 5-km running time-trial performance. Secondary outcomes will include exercise-induced fluid and sweat loss, urinary hydration markers, sweat electrolyte concentrations, physiological responses, exercise economy, substrate utilization, blood lactate concentration, perceived exertion, thirst, and thermal sensation.

Studieöversikt

Status

Har inte rekryterat ännu

Betingelser

Studietyp

Interventionell

Inskrivning (Beräknad)

20

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 45 år (Vuxen)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Age 18-45 years
  • Sex: men and premenopausal women
  • Continuous running training for at least 12 months
  • At least 3 running training sessions per week
  • Willingness and ability to complete the treadmill exercise protocol: 60 minutes of running at 60% of the running velocity corresponding to VO₂max, followed by a 5-km running time trial
  • Medical clearance for participation in maximal and prolonged exercise testing

Exclusion Criteria:

  • Age <18 or >45 years
  • Postmenopausal women
  • Use of betaine, choline, folic acid/folate, or vitamin B12 supplements within 3 months prior to study participation
  • Current musculoskeletal injury or injury occurring within the previous 2 months
  • Uncontrolled arterial hypertension
  • Pregnancy or breastfeeding
  • Diabetes requiring insulin therapy or inadequately controlled diabetes
  • Active or severe liver disease, including ALT or AST >3× the upper limit of normal
  • Renal impairment, including eGFR <60 mL/min/1.73 m²
  • Untreated or unstable thyroid disease, including hypothyroidism or hyperthyroidism
  • Gastrointestinal disease that may affect nutrient absorption
  • Kidney disease, cardiovascular disease, irritable bowel syndrome, or adrenal disease
  • Use of diuretics, SGLT2 inhibitors, laxatives, or glucocorticoids
  • Any medical contraindication to physical exercise and/or failure to obtain medical clearance for exercise testing
  • Elevated body temperature at the time of testing
  • Cystic fibrosis

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Övrig
  • Tilldelning: Randomiserad
  • Interventionsmodell: Crossover tilldelning
  • Maskning: Trippel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Betaine → Placebo Sequence

Participants will first complete the betaine-enriched hyperhydration condition. After the washout period, they will complete the placebo hyperhydration condition.

Anhydrous betaine (trimethylglycine) will be administered as a single dose of 0.07 g/kg body mass, dissolved in a commercially available sports drink (5 mL/kg body mass), 150 minutes before exercise. The betaine-containing drink will constitute the first bolus of a standardized pre-exercise hyperhydration protocol providing a total fluid intake of approximately 25 mL/kg body mass over 120 minutes.

Participants will receive the same commercially available sports drink (5 mL/kg body mass) without added betaine 150 minutes before exercise. This will be followed by four additional fluid boluses of mineral water (5 mL/kg each) administered at 120, 90, 60, and 30 minutes before exercise, for a total pre-exercise fluid intake of approximately 25 mL/kg body mass.

Experimentell: Placebo → Betaine Sequence

Participants will first complete the placebo hyperhydration condition. After the washout period, they will complete the betaine-enriched hyperhydration condition.

Anhydrous betaine (trimethylglycine) will be administered as a single dose of 0.07 g/kg body mass, dissolved in a commercially available sports drink (5 mL/kg body mass), 150 minutes before exercise. The betaine-containing drink will constitute the first bolus of a standardized pre-exercise hyperhydration protocol providing a total fluid intake of approximately 25 mL/kg body mass over 120 minutes.

Participants will receive the same commercially available sports drink (5 mL/kg body mass) without added betaine 150 minutes before exercise. This will be followed by four additional fluid boluses of mineral water (5 mL/kg each) administered at 120, 90, 60, and 30 minutes before exercise, for a total pre-exercise fluid intake of approximately 25 mL/kg body mass.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
5-km Running Time-Trial Performance
Tidsram: During the 5-km treadmill time trial performed after the 60-minute running preload and a 5-minute recovery period in each experimental trial.

Time required to complete a 5-km treadmill running time trial, expressed in seconds. Participants will be instructed to complete the distance as quickly as possible and will be allowed to adjust treadmill speed throughout the trial. Lower completion time indicates better performance.

During the 5-km treadmill time trial performed after the 60-minute running preload and a 5-minute recovery period in each experimental trial.

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Sweat rate
Tidsram: From immediately before the 60-minute running preload to completion of the subsequent 5-km time trial during each experimental trial.

Whole-body sweat rate will be estimated from the change in body mass from immediately before exercise to completion of the 5-km time trial, adjusted for fluid intake and urine output, if applicable, and expressed as L/h. Body mass will be measured using the calibrated electronic scale integrated with the BOD POD system (COSMED, Italy) and expressed in kilograms (kg). Changes in body mass will also be calculated and reported as a percentage of pre-exercise body mass (%).

From immediately before the 60-minute running preload to completion of the subsequent 5-km time trial during each experimental trial.

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Sweat sodium concentration
Tidsram: Between minutes 30 and 60 of the 60-minute running preload during each experimental trial.

Sodium concentration will be measured in sweat samples collected from standardized sites on the forearm and thigh during exercise. Sweat samples will be collected between minutes 30 and 60 of the 60-minute running preload. Sodium concentration will be analyzed using a HORIBA ion-selective electrode analyzer and reported in mmol/L.

Between minutes 30 and 60 of the 60-minute running preload during each experimental trial.
Sweat Potassium Concentration
Tidsram: Between minutes 30 and 60 of the 60-minute running preload during each experimental trial.

Potassium concentration will be measured in sweat samples collected from standardized sites on the forearm and thigh during exercise. Sweat samples will be collected between minutes 30 and 60 of the 60-minute running preload. Sweat potassium concentration will be analyzed using a HORIBA ion-selective electrode analyzer and reported in mmol/L.

Between minutes 30 and 60 of the 60-minute running preload during each experimental trial.
Blood lactate concentration
Tidsram: Immediately after the 60-minute running preload and immediately after the 5-km time trial during each experimental trial.

Blood lactate concentration will be measured using a portable Lactate Scout 4 analyzer. Measurements will be obtained immediately after completion of the 60-minute running preload and immediately after completion of the subsequent 5-km time trial. Blood lactate concentration will be reported in mmol/L.

Immediately after the 60-minute running preload and immediately after the 5-km time trial during each experimental trial.
Heart rate
Tidsram: Continuously during the 60-minute running preload and the subsequent 5-km time trial in each experimental trial.

Heart rate will be monitored continuously using a Garmin chest-strap heart rate monitor with integrated electrodes throughout the 60-minute running preload and the subsequent 5-km time trial. Outcome variables will include mean heart rate during the 60-minute preload, mean heart rate during the 5-km time trial, and maximal heart rate achieved during the 5-km time trial. Heart rate will be reported in beats per minute (bpm).

Continuously during the 60-minute running preload and the subsequent 5-km time trial in each experimental trial.
Core Body Temperature
Tidsram: Continuously during the 60-minute running preload and the subsequent 5-km time trial in each experimental trial.

Core body temperature will be monitored continuously using a CORE body temperature sensor attached to the Garmin chest strap throughout the 60-minute running preload and the subsequent 5-km time trial. Outcome variables will include mean core body temperature during the exercise protocol and the highest core body temperature recorded during the exercise protocol. Temperature will be reported in degrees Celsius (°C).

Continuously during the 60-minute running preload and the subsequent 5-km time trial in each experimental trial.
Running Economy
Tidsram: During the final 10 minutes (minutes 50-60) of the 60-minute running preload in each experimental trial.

Running economy will be assessed by breath-by-breath indirect calorimetry using a QUARK RMR metabolic system during the final 10 minutes (minutes 50-60) of the 60-minute running preload. Running economy will be quantified as mean oxygen consumption (VO₂) relative to body mass at the standardized running velocity and expressed as mL·kg-¹·min-¹. Lower oxygen consumption at the same running velocity indicates better running economy.

During the final 10 minutes (minutes 50-60) of the 60-minute running preload in each experimental trial.
Respiratory Exchange Ratio
Tidsram: During the final 10 minutes (minutes 50-60) of the 60-minute running preload in each experimental trial.

Respiratory exchange ratio (RER) will be assessed by breath-by-breath indirect calorimetry using a QUARK RMR metabolic system during the final 10 minutes (minutes 50-60) of the 60-minute running preload. RER will be calculated as the ratio of carbon dioxide production (VCO₂) to oxygen consumption (VO₂) and expressed as a unitless value. The mean RER over the measurement period will be used for analysis.

During the final 10 minutes (minutes 50-60) of the 60-minute running preload in each experimental trial.
Urine specific gravity
Tidsram: Immediately before the 60-minute running preload and immediately after completion of the 5-km time trial in each experimental trial.

Urine specific gravity (USG) will be measured using a URIT-31 urine analyzer from urine samples collected immediately before the 60-minute running preload and after completion of the subsequent 5-km time trial. USG will be reported as a dimensionless value. Urine osmolality will also be estimated from USG using a predefined conversion equation and reported in mOsm/kg.

Immediately before the 60-minute running preload and immediately after completion of the 5-km time trial in each experimental trial.
Rating of Perceived Exertion (RPE)
Tidsram: At minutes 30, and 60 of the 60-minute running preload and immediately after completion of the 5-km time trial during each experimental trial.

Rating of perceived exertion will be assessed using the Borg 6-20 Rating of Perceived Exertion scale, ranging from 6 ("no exertion at all") to 20 ("maximal exertion"). RPE will be recorded at 15-minute intervals during the 60-minute running preload and immediately after completion of the 5-km time trial.

At minutes 30, and 60 of the 60-minute running preload and immediately after completion of the 5-km time trial during each experimental trial.
Thirst Sensation
Tidsram: Immediately before the 60-minute running preload, at minutes 30,and 60 of the preload, and immediately after completion of the 5-km time trial during each experimental trial.

Perceived thirst will be assessed using a 9-point categorical thirst sensation scale ranging from 1 ("not thirsty at all") to 9 ("very, very thirsty"). Participants will be asked to rate their current sensation of thirst at each measurement time point.

Immediately before the 60-minute running preload, at minutes 30,and 60 of the preload, and immediately after completion of the 5-km time trial during each experimental trial.
Thermal Sensation
Tidsram: Immediately before the 60-minute running preload, at minutes 30 and 60 of the preload, and immediately after completion of the 5-km time trial during each experimental trial.

Thermal sensation will be assessed using a 17-point thermal sensation scale ranging from 0 to 8 in 0.5-point increments, with 0 representing "unbearably cold", 4 representing "neutral", and 8 representing "unbearably hot". Participants will rate their whole-body thermal sensation at each measurement time point.

Immediately before the 60-minute running preload, at minutes 30 and 60 of the preload, and immediately after completion of the 5-km time trial during each experimental trial.

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 oktober 2026

Primärt slutförande (Beräknad)

31 maj 2027

Avslutad studie (Beräknad)

30 december 2027

Studieregistreringsdatum

Först inskickad

18 september 2026

Först inskickad som uppfyllde QC-kriterierna

18 september 2026

Första postat (Faktisk)

25 september 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

25 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

18 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • BETxSWEAT

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

OBESLUTSAM

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera